Our Pipeline

Utilizing Our Proprietary Technologies to Create Life-Changing Therapies

Internal Development Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Highlights
XCART™ Platform B-Cell Non-Hodgkin Lymphoma
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Advancing toward IND filing

PolyXen - Partnered Drug Delivery Programs

Program Indication Partners
PolyXen® Next Generation Half-Life Extension Platform Technology Takeda Receiving royalties on net sales through exclusive license agreement in the field of coagulation disorders
ErepoXen (PSA-EPO) Treatment of anemia in patients with chronic kidney disease (CKD) Partner filed registration dossier in Russia